Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
This grant funds research into the mechanisms by which incretin mimetics may influence cancer risk.
About this program
The grant focuses on understanding the biological mechanisms that may link the use of incretin mimetics to cancer risk. It aims to support innovative research that explores the potential effects of these medications on cancer development and progression. This funding opportunity is intended for researchers in the fields of oncology, endocrinology, and pharmacology who are investigating the implications of incretin mimetics in cancer risk assessment. Eligible applicants include academic institutions, nonprofit organizations, and other research entities that can contribute to this area of study. The grant encourages interdisciplinary approaches and collaboration among researchers to enhance the understanding of incretin mimetics and their potential impact on cancer risk. Successful proposals should demonstrate a clear research plan, methodology, and the potential for significant contributions to the field.
Eligibility
Academic institutions, nonprofit organizations, and research entities focused on cancer research.
Requirements
- Research proposal detailing the study of incretin mimetics and cancer risk
- Interdisciplinary collaboration encouraged